Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

June 4, 2026 | Poster
Pelareorep induces expansion of mutant KRAS-specific TIL clones in the blood
Trauger, Richard et al; Previously presented at the 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026
December 6, 2023 | Poster
T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes 
Trauger, Richard et al, Previously presented at the 2023 San Antonio Breast Cancer Symposium®; December 5-9, 2023
November 3, 2023 | Poster
Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Olea, Julian et al. Previously presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023
October 3, 2023 | Poster
Multiplex analysis of the tumor immune microenvironment during treatment with atezolizumab/pelareorep/letrozole reveals novel immune-tumor interactions
Dadrastoussi, Homa et al.
December 1, 2022 | Poster
Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway andtumor inflammation signature in early breast cancer patients – results of the AWARE-1 trial
H. Loghmani, J Gavila, L. Manso, R. Trauger, F. Salvador, T. Pascual, A. Prat, Matt Coffey, T. Heineman
November 8, 2022 | Poster
The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study
González-Navarro, E.A et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022
May 3, 2022 | Poster
The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients – Results from AWARE-1 study
Gavilá, Joaquín et al, Previously presented at the European Society for Medical Oncology Breast Cancer 2022 Meeting; May 3-5, 2022
April 10, 2021 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
Manso L et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract CT191

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolyticsbiotech.com.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch